Background: ATP synthesis and cardiac contraction-related protein production are accelerated in the immature fetal heart by antenatal glucocorticoids (GC). This study investigated the structural maturity of the myocardium and underlying signal pathway associated with cardiac growth in fetal rats that received antenatal GC. Methods and Results: Dexamethasone (DEX) was given to pregnant rats for 2 days from day 17 or day 19 of gestation, and the hearts of 19 and 21 day fetuses and 1-day-old neonates were analyzed. Although irregular myofibril orientation was observed morphologically in 19 day fetal hearts, the myofibril components were organized in fetuses after DEX. The cross-sectional area of the myocardium and Ki-67-positive cells were significantly increased in fetal DEX groups, suggesting that cardiac enlargement resulted from myocyte proliferation. Glycogen synthase kinase-3b (GSK-3b) protein was significantly decreased in fetal DEX groups. b-Catenin and vascular endothelial growth factor protein were also significantly increased. Furthermore, increased cardiomyocyte proliferation appeared to be mediated by GC receptors after culture with DEX in vitro. Conclusions: Antenatal DEX induces structural maturity accompanying cardiomyocyte proliferation in the premature fetal rat heart, and GSK-3b and b-catenin are thought to contribute to cardiac growth.
The use of antenatal glucocorticoid (GC) in preterm delivery significantly decreases the incidence of mortality and morbidity due to life-threatening complications such as respiratory distress syndrome or intraventricular hemorrhage, and evidence of its effectiveness is gradually increasing. [1] [2] [3] Although adequate pulmonary development at birth is the most important component, structural and functional heart development is also necessary.
We previously demonstrated that immature fetal rat hearts received developmental benefits from antenatal GC, [4] [5] [6] [7] which increases the expression of the contraction-related proteins troponin-T 4 and sarcoplasmic reticulum transport ATPase 2a. 5 In addition, ATP synthesis is accelerated through increases in creatine kinase (CK) and the glycolytic enzyme a-enolase. 6, 7 Regulation of the cardiovascular system depends on sympathetic autonomic control. Imbalances in the autonomic system are involved in the pathogenesis of cardiovascular disease. Cardiac autonomic balance was reported to be preserved in human neonates exposed to a single antenatal GC dose. 8 GC, however, has also been reported to be associated with a wide range of adverse effects on the cardiovascular system. 9 Therefore, basic research is required to clarify the benefits and adverse effects of antenatal GC on cardiovascular function.
Cardiac hypertrophy has been observed in newborns given GC for the treatment of various diseases. [10] [11] [12] Cardiac hypertrophy is characterized by increased ventricular mass and wall thickness and is induced by pathological or physiological stimuli. [13] [14] [15] Physiological hypertrophy is reversible and occurs during maturation and pregnancy without adverse effects on cardiac function. 16 The development of the fetal heart requires cardiomyocyte proliferation and morphogenic differentiation in the myocardium. In contrast, pathological hypertrophy is accompanied by maladaptive responses such as fibrosis, chamber dilation, and hemodynamic decompensation. We also found that antenatal GC increased wall thickness in the immature fetal rat heart. 4 It is difficult to clarify whether the increase in wall thickness in the fetal heart after antenatal GC represents physiological or pathological hypertrophy. Furthermore, the molecular mechanisms leading to cardiac hypertrophy remain unclear.
McMullen et al. reported that phosphatidylinositol-3 kinase (PI3K) is essential for the induction of physiological cardiac hypertrophy. 17 PI3K generates phospholipids known to regulate Akt activity in promoting cardiac hypertrophy. 18 Our previous study reported that Akt-1 protein level significantly increased in the fetal hearts with GC.
In this study, we investigated whether antenatal GC affects the downstream mechanisms of Akt-1 underlying the development of cardiac hypertrophy in fetal rats.
Methods

Animals and experimental protocols
Eight-week-old pregnant Wistar rats were purchased from CLEA (Tokyo, Japan). Dexamethasone (DEX) was purchased from Wako Pure Chemical Industries (Osaka, Japan) and dissolved in sesame oil. The pregnant rats were randomly divided into two groups to receive either DEX or vehicle (sesame oil) as a control at a dose of 0.5, 1.0, or 2.0 mg/kg given s.c. on gestational days 17 and 18, or 19 and 20, or 20 and 21. The fetuses were delivered by cesarean section on gestational days 19 and 21, and then the 1-day-old neonates were killed under pentobarbital anesthesia. The hearts were immediately removed and frozen at À80°C until use. The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Institute of Experimental Animals, St Marianna University School of Medicine. The protocol was approved by the Animal Research Committee, Institute for Animal Experimentation, St Marianna University Graduate School of Medicine (permit number 1406013). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.
Cardiac morphometry and cardiomyocyte nuclei
The morphometric procedure provides reliable information on the volume composition of the myocardium. The hearts of neonatal rats were removed as described. The heart tissue was sectioned in the transverse axial direction to the papillary muscle. The 3-lm-thick paraffin-embedded sections were stained with hematoxylin and eosin (HE). Microscopy was performed using an Olympus CX41 microscope (Olympus, Tokyo, Japan). The cross-sectional area of the myocardium was measured using the public-domain software NIH Image J 1.48 (developed at the US National Institutes of Health and available on the Internet at http://imagej.nih.gov/ij/download,html).
The cell density of cardiomyocytes can be estimated by counting the number of nuclei in cardiomyocytes, because a fetal myocyte has only a single nucleus. 20 The nuclei of cardiomyocytes were counted in one microscopy field of view at 9400 magnification, and the mean was calculated from 12 non-adjacent sections of the right ventricle (RV) and LV.
Immunohistochemistry
On immunohistochemistry, cardiac tissues were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase in the tissue sections was inactivated with 0.1% hydrogen peroxidase. Immunoreactivity in the tissue sections was demonstrated using a Dako Envision Systems kit (Carpinteria, CA, USA) according to the manufacturer's instructions. The tissues were then counterstained with hematoxylin. The ratio of positive cells/total cells was calculated by counting 600 cardiomyocytes in six non-adjacent fields, and the mean number of positive cells in the total number of cardiomyocytes was determined.
Western blot analysis
The cardiac tissue was homogenized with lysis solution (TrisHCl, 50 mmol/L; pH 7.4; EDTA, 1 mmol/L; 0.001% leupeptin). The samples (15 lg) were resolved on 5-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (e-PAGEL, ATTO, Tokyo, Japan). The membrane was blocked with 5% skim milk in Tris-buffered saline containing Tween 20 (NaCl, 150 mmol; Tris-HCl, 100 mmol/L; pH 7.5, Tween, 0.5%) overnight at 4°C. The blots were proved with anti-glycogen synthase kinase (anti-GSK)-3b poly-antibody (Ab), anti-phosphorylated (p)-GSK-3b polyAb, anti-b-catenin polyAb (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-vascular endothelial growth factor (VEGF) polyAb (Abcam, Tokyo, Japan), and anti-a-tubulin polyAb (Wako, Tokyo, Japan) for 2 h at room temperature. Reactive proteins were viewed under enhanced chemiluminescence (Western Sure Premium Chemiluminescent Substrate; LI-COR, Lincoln, NE, USA). The band density was detected using a C-Digit Blot scanner (LI-COR). The intensity of the detected bands was analyzed using Image Studio version 4.0.21 (LI-COR).
In vitro cardiomyocyte culture
Cardiomyocytes of 1-day-old neonates were obtained from Lonza Walkersville (Walkersville, MD, USA). The cells (1.5 9 10 5 ) were cultured in 96-well plates (Asahi Techno Glass, Chiba, Japan) with rat cardiomyocyte basal medium (Lonza Walkersville) containing 8% horse serum and 8% fetal bovine serum with gentamicin (15 units/mL) for 24 h at 37°C under an atmosphere of 5% CO 2 and 95% O 2 . After 24 h, the medium was replaced with new medium containing 200 lmol/L bromodeoxyuridine, and the cells were cultured with DEX 1 lmol/L for 24 h after pre-incubation with the GC receptor antagonist RU486 (10 lmol/L) for 1 h.
Cell proliferation assay
Cardiomyocyte proliferation was evaluated in the 3-(4,5-dimethyltiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) cell-titer 96 aqueous one-solution cell proliferation assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. The cells (1.5 9 10 4 ) were incubated with DEX (1 lmol/L) in 96-well plates (Iwaki Glass, Tokyo, Japan) for 24 h. The cells were cultured with DEX for 24 h after pre-incubation with RU486 10 lmol/L, and then the MTS substrate was added to each well in a ratio of 20 lL MTS for every 200 lL of culture medium, and the mixture was incubated for 2 h at 37°C.
Absorbance was measured at 490 nm with a microplate reader (Multiskan, Thermo Labsystems, Ventaa, Finland).
Statistical analysis
All results are presented as mean AE SEM. Differences between groups were determined using the Steel-Dwass multiple-comparison method. P < 0.05 was assumed to represent a statistically significant difference. Analysis was performed using JMP pro12 (SAS Institute, Cary, NC, USA).
Results
Histology and cross-sectional morphometry
We first observed the histological structure of 19 day fetal-5 day neonatal rat hearts. The myocardia of the 19 day fetal controls were clearly morphologically different from those of the 21 day fetal and neonatal controls. HE staining showed irregular myofibril components and increased interstitial space in both the LV and RV of 19 day fetal controls. The myofibril components gradually organized after growth (Fig. 1a) . Organization of the myofibril components was seen after DEX in 19 and 21 day fetal hearts (Fig. 1a) .
Because fetal and neonatal myocytes have only one nucleus, the nuclei of cardiomyocytes were counted under a microscope at 4009 magnification to calculate the cell density of cardiomyocytes. Fewer nuclei were present in 19 day fetal myocytes compared with 21 day fetal and 1 day neonatal myocytes (Fig. 1b) . DEX did not affect nuclei number in fetuses and neonates, suggesting that DEX induced growth via hyperplasia of myofibrils.
The cross-sectional area of the heart was measured using NIH imaging software. Serial histological analysis was performed in hearts from 19 day fetuses to 1 day neonates. The cross-sectional area of the myocardium in the 1 day neonatal control group was used as the 100% reference. The mean heart cross-sectional area of 19 day fetuses (70.51 AE 6.66%, P < 0.05) was smaller than that of 21 day fetuses (81.61 AE 3.68%, P < 0.05) and of 1 day neonates (100.00 AE 4.88%; Fig. 1c ). Furthermore, antenatal DEX (19 day fetuses, 91.04 AE 1.95%; 21 day fetuses, 102.76 AE 2.27%; 1 day neonates, 112.55 AE 1.58%, P < 0.05) significantly increased the crosssectional area compared with that of the respective controls (Fig. 1c) .
Ki-67 production in cardiac tissue
To confirm whether antenatal DEX affects cardiomyocyte proliferation, we performed immunohistochemical staining using the cell proliferation marker Ki-67. 21 Ki-67-positive cells was significantly increased in the LV and RV of 19 130-150% increases in Ki-67-positive cells in the 19 and the 21 day fetal hearts. There was no difference between the LV and the RV in the respective groups. There was also no significant difference in Ki-67 production between the antenatal DEX and control groups in 1 day neonates (control group: LV, 32.67 AE 1.20% and RV, 28.5 AE 3.63%; DEX group: LV, 27.00 AE 3.68% and RV, 14.83 AE 2.59%).
Cardiomyocyte proliferation
Cardiomyocyte proliferation after co-culture with DEX was evaluated using the in vitro MTS assay. Proliferation was significantly increased in the DEX group (109.97 AE 1.00%) compared with the controls (100.00 AE 1.62%). Moreover, preincubation of cardiomyocytes with the GC receptor antagonist RU-486 significantly inhibited DEX-induced cell proliferation (86.14 AE 1.56%). RU-486 alone did not affect cell proliferation (83.94 AE 2.56%; Fig. 2c ).
Glycogen synthase kinase-3b protein
Glycogen synthase kinase-3b is an important negative regulator of downstream substrates that are inhibited by Akt. GSK3b protein production was confirmed using western blotting (Fig. 3a) . GSK-3b protein level significantly decreased in 19 day fetuses given DEX 2.0 mg/kg (35.21 AE 4.46%) compared with the controls (153.42 AE 21.27%, P < 0.05). The 19 day fetal hearts treated with DEX 2.0 mg/kg also had decreased GSK-3b protein levels compared with the 0.5 mg/ kg DEX group (111.52 AE 12.35%, P < 0.05). GSK-3b protein tended to decrease in the 21 day fetal DEX group compared with controls.
On immunohistochemistry of the LV and RV of rat fetuses, the number of GSK-3b-positive cells significantly decreased in the 19 day fetal LV after antenatal DEX (57.17 AE 2.33%) compared with controls (75.17 AE 2.23%; P < 0.05; Fig. 3b,c) . In the 21 day fetal RV and 1 day neonatal RV DEX groups, GSK-3b positive cells were significantly decreased compared with the respective controls.
Phosphorylated GSK-3b protein
Recently, it has been shown that the Akt pathway promotes cardiomyocyte survival, cell proliferation, and physiological hypertrophy. [22] [23] [24] Akt activation leads to inactivation of GSK3b with ubiquitination and phosphorylation. 25 p-GSK-3b protein in cardiac tissue tended to increase in the 19 and 21 day fetal DEX 1.0 mg/kg groups (1.0 mg/kg: 19 day, 99.04 AE 15.36%; 21 day, 96.04 AE 17.11%) compared with the respective controls (19 day, 70.90 AE 3.88%; 21 day, 71.14 AE 11.33%). There were no differences in p-GSK-3b protein level between the fetal and neonatal control and DEX groups. There was also no difference between the 1-day-old neonatal control and DEX groups (Fig. 3d) .
We performed immunohistochemistry using an anti-phosphorylation-specific GSK-3b (Ser9) antibody. Compared with control groups, the production of p-GSK-3b significantly increased after antenatal DEX in 19 day (LV, 47.33 AE 3.56% vs 71.33 AE 6.74%; RV, 50.83 AE 0.70% vs 65.33 AE 2.73%, respectively, P < 0.05) and 21 day fetuses (LV, 41.00 AE 1.90% vs 64.17 AE 1.47%, respectively, P < 0.05). There was no difference between the 1 day neonatal control and DEX groups (65.83 AE 8.13% vs 65.17 AE 2.93%; Fig. 3e,f) .
b-Catenin protein b-Catenin activation robustly enhanced the proliferative capacity of early cardiomyocytes. b-Catenin is produced abundantly by Akt-dependent inactivation of GSK-3b. 22, 26 We examined whether antenatal DEX increased the production of b-catenin and found that b-catenin protein level increased significantly in 19 day fetuses given DEX 1.0 mg/kg (133.58 AE 6.23%; P < 0.05) and 2.0 mg/kg (148.36 AE 4.49%; P < 0.05) compared with the controls (89.37 AE 5.02%; Fig. 4a ). In 21 day fetuses, b-catenin protein level tended to increase after antenatal DEX.
b-Catenin is present in the cytoplasm, where it functions as an intranuclear transcription factor, but is not present in the cell membrane. Figure 4b ,c shows the immunohistochemistry of b-catenin localization in the LV and RV. b-Catenin-positive cells were observed in the cytoplasm and cardiomyocyte nuclei and were significantly increased in the 19 day fetal DEX group (LV, 65.67 AE 1.09%; RV, 71.00 AE 1.79%) compared with the controls (LV, 51.83 AE 1.74%; RV, 48.00 AE 1.71%, respectively; P < 0.05). There was no difference in the number of b-catenin-positive cells between the LV and RV in the fetal DEX group.
VEGF protein
Proportional growth of the capillary network is required for physiological cardiac hypertrophy. VEGF is involved in the regulation of coronary angiogenesis in physiological cardiac hypertrophy. 27 Inhibition of GSK-3b and activation of the Fig. 5b,c) .
Discussion
The present study has shown that antenatal DEX promotes the structural maturity of the myocardium and that the mechanisms underlying cardiac growth are associated with cardiomyocyte proliferation. We previously reported that antenatal GC accelerates the development of cardiac function with concomitant cardiac enlargement. 4 That enlargement appears to be due to hypertrophy and hyperplasia of cardiomyocytes during late gestation or the early postnatal period. 29 We hypothesized that the phenomenon of cardiomyocyte hypertrophy supports growth and undertook the present experiments to confirm this.
Mildenhall et al. demonstrated that repeated exposure to antenatal GC did not affect blood pressure or myocardial thickness in infants postnatally. 30 Increased cardiac wall thickness, however, was reported in a fetal animal model of GC infusion exposure. 31 DEX is known to reduce cellular density and induce abnormal myocardial hypertrophy and hyperplasia with fibrosis in premature infants with bronchopulmonary dysplasia. 32, 33 Although incomplete organization of myofibril components in both the LV and RV in 19 and 21 day rat fetuses was seen on histochemistry in the present study, many myofibrils were organized in a parallel arrangement in the hearts in the antenatal DEX groups.
On microscopy, the cell number of fetal and neonatal cardiomyocytes after DEX was not affected. We found, however, that the cross-sectional area of the myocardium in 19 and 21 day fetal rats in the antenatal DEX groups significantly increased compared with the controls. Interestingly, the increase in cross-sectional area in the 21 day DEX groups was equal to that in the 1 day neonatal control group. This suggests that antenatal DEX completed the fascicular disarray of myofibrils and may have accelerated cardiac growth accompanying cardiac enlargement. When we observed the morphology of cardiomyocyte on HE staining, cardiomyocyte hypertrophy was not seen.
The cardiomyocyte proliferative ability of the murine fetal heart is very high during the early embryonic stage; 10,34 declines thereafter; and then is restored in the 5 days after birth.
1,11
When we evaluated the production of the cell proliferation marker Ki-67 on immunohistochemistry, fewer Ki-67-positive cells were seen in 1 day neonatal controls than in 19 day fetal controls. Ki-67-positive cells were significantly increased in 19 and 21 day fetuses exposed to antenatal DEX compared with controls. No changes in the number of Ki-67-positive cells, however, were seen in 1 day neonates. The proliferative ability of fetal cardiomyocytes was therefore confirmed.
We next investigated whether the increased cell proliferation after DEX was mediated through GC receptors using cultured cardiomyocytes in the in vitro MTS assay. The cells were treated with DEX after pre-incubation with the GC receptor RU486. RU486 pre-incubation significantly inhibited the increase in DEX-induced proliferation, suggesting that the sequence of responses is mediated through GC receptors. GC is mediated through a glucocorticoid receptor (GR) isoform, GRa and GRb. Stechschulte et al. reported that overexpression of GRb increased Akt phosphorylation, resulting in fetal growth in mouse embryonic fibroblast cells. 35 We speculate that antenatal GC mediates GRb and activates the Akt pathway in cardiomyocyte proliferation.
Signaling pathways connecting growth factors and their downstream mediators play a role in the development of pathological and physiological cardiac hypertrophy. The precise molecular mechanisms resulting in cardiac hypertrophy in those phenomena, however, remain unclear. Phosphoinositide 3-kinase (PI3K) are known to regulate physiological cardiac hypertrophy such as developmental heart growth and cell survival. [22] [23] [24] The PI3K-Akt pathway participates in the cardiac hypertrophic program. Akt-1 is mainly abundant in cardiac tissue and is required for physiological cardiac growth. Akt-1 activation is absolutely required for physiological growth in insulin-like growth factor stimulation via exercise training in postnatal murine cardiac monocytes. 24 Our previous study demonstrated that Akt-1 protein level was significantly increased in 19 and 21 day fetuses in the DEX groups. 19 Thus, the increases in Akt-1 in fetal hearts with antenatal DEX supported cardiac enlargement, although it cannot be concluded that increased Akt protein expression alone is responsible for cardiac hypertrophy accompanied by growth.
The GSK-3b inhibition by Akt protein is an important negative regulator of downstream transcriptional factors such as bcatenin and GATA-4.
36 GSK-3b is constitutively active under unstimulated conditions and induces cardiac development through Wnt signaling. The inhibition of GSK-3b activates Wnt/b-catenin signaling during the proliferation or differentiation of early beating cardiac myocytes and robustly enhances the proliferative capacity of early cardiomyocytes. 37 In the present study, antenatal DEX dose-dependently decreased GSK-3b protein level in 19 day fetal hearts. GSK-3b protein level in 21 day fetuses tended to be lower, while that in 1 day neonates was somewhat lower than that in 19 day fetuses. Antenatal DEX did not affect GSK-3b protein level in 21 day fetuses or in 1 day neonates. GSK-3b production in fetal LV and RV tissue was approximately the same, as seen on western blotting. There were no changes in p-GSK-3b protein level between the control and DEX groups in either fetal or neonatal cardiac tissue. On immunohistochemistry, the production of p-GSK-3b significantly increased in the 19 and 21 day fetal LV and 19 day RV after antenatal DEX. This suggests that p-GSK-3b activation may act predominantly in the LV rather than the RV. b-Catenin is a positive regulator of proliferation for cardiac growth, and bcatenin protein level was also significantly increased in 19 day fetal hearts in the DEX 1.0 and 2.0 mg/kg groups; similar results were obtained on immunohistochemistry.
In addition, GSK-3b directly regulates the subcellular localization of the zinc finger transcription factor GATA-4. We previously demonstrated an increase in GATA-4 in fetal hearts after DEX exposure, and found that GATA-4 induces increases in the myocardium contraction-related protein troponin T, suggesting that it plays a role in cardiac development. 4 GSK-3b is essential for the cardiac growth of immature fetal hearts.
Finally, we found that the production of the angiogenesis factor VEGF was significantly increased in 19 day fetal hearts after antenatal DEX exposure. Akt-1-deficient mice have reduced survival with a decrease in endothelial cell density in the myocardium and attenuated expression of VEGF in the fetal heart. 38 Physiological hypertrophy is therefore dependent on the proportional expansion of the capillary network. Yao et al. reported that the underlying mechanism, Akt/protein kinase B and phosphorylated GSK-3b, lead to functional expression of both VEGF and its receptor VEGF-R2 in the rat myocardium. 39 Taken together, this indicates that phosphorylated GSK-3b is capable of inducing myocardial neovascularization via VEGF activation. Figure 6 illustrates the molecular network involving GC, PI3K, Akt-1, p-GSK-3b, b-catenin and VEGF. Antenatal GC enhances PI3K, and PI3K produces Akt-1. Moreover, Akt-1 accelerates both p-GSK3b and VEGF expression. In conclusion, antenatal GC induces structural maturity accompanying cardiomyocyte proliferation in the premature fetal heart, and Akt/GSK-3b/b-catenin are thought to contribute to cardiac growth. Antenatal GC exposure has been reported to promote structural maturation in the fetal heart. The finding that GC exposure increases cardiomyocyte proliferation in the fetal heart is able to be explained by the promotion of proliferation-related transcription factors through the GC receptor in the fetal heart. Our studies have demonstrated that antenatal GC accelerates the growth of immature cardiac functions. [4] [5] [6] [7] Thus, the proliferative capacity of immature cardiomyocytes may be an adaptation to the new environment after birth, resulting in prevention of heart failure.
